investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Clonal Evolution and Prospective Isolation of Myelodysplastic Syndrome Initiating
James Y. Chen
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
James Y. Chen
Stanford University
Stanford, United States
Related projects
Charalampos Kalodimos
Mechanisms of autoinhibition and activation of the Abl kinase
Leukaemia
Hao Yuan Kueh
Single cell analysis of hematopoietic cell fate determination
Leukaemia
Birgit Knoechel
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemia
Leukaemia
Ping Xie
Molecular mechanisms of B cell malignant transformation
Leukaemia
Dongsu Park
Role of osteogenic stem cells in bone regeneration and repair in vivo
Leukaemia
Dean W Felsher
Mechanisms by which Oncogene Inactivation Elicits Tumor Cell Death
Leukaemia
Paul B. Jacobsen
Internet-Assisted Cognitive Behavior Intervention for Targeted Therapy Fatigue
Leukaemia
Derek B. Sant'Angelo
Control of cytokine production by human NK cells
Leukaemia
Kimberly Stegmaier
Validating Syk as a Target for AML Therapy
Leukaemia